BRAF and colorectal carcinoma: In MSS CRCs, a large-scale pooled analysis of prospective randomized trials (n = 3278) pointed out that BRAF-mutated CRC revealed a significantly worse association with OS (HR 1.84, 95% CI 1.14–2.97), but not with RFS (HR 1.36, 95% CI 0.86–2.16) in Stage II/III disease [45].